Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo

Jame Abraham, MD

216.444.6833

Jame Abraham, MD
Department: Hematology and Oncology
Director, Breast Oncology Program
Location: Cleveland Clinic Main Campus
Mail Code R35
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6833
DeskDesk:216.445.0150
Surgeon:
No
Type of Doctor:
Adults Only

Biographical Sketch

Jame Abraham, MD, FACP,  is the Director of the Breast Oncology Program at Taussig Cancer Institute and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program. Dr. Abraham is also a professor of medicine at Cleveland Clinic Lerner College of Medicine.

Dr. Abraham completed his residency at the University Of Connecticut School Of Medicine, followed by a Medical Oncology fellowship from the National Cancer Institute (NCI) and Hematology Fellowship from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). Dr. Abraham earned his medical degree from Calicut Medical College, Kerala, India.

At the NCI, he was the study chair of several early-phase clinical trials that included novel treatment for breast cancer such as Ixabepilone, which was approved by FDA in 2007. During his fellowship, Dr. Abraham edited the first edition of the Bethesda Handbook of Oncology (Lippincott Williams and Wilkins) and now it is one of the best-selling oncology textbooks in the world. It is considered the standard textbook by many universities and hospitals across the world.

After finishing fellowship, Dr. Abraham joined West Virginia University in 2001 as an Assistant Professor. He was appointed Chief of Hematology/Oncology in 2005. He was later appointed as the first Bonnie Wells Wilson Distinguished Professor of Breast Cancer Research, and Professor of Medicine of West Virginia University (WVU).

At WVU, Dr. Abraham established the first comprehensive breast cancer program in the state of West Virginia. He received a grant from Department of Defense (Idea Award and Career Development Award) to study chemotherapy-induced cognitive impairment. His outstanding work in patient care was recognized by the Excellence in Clinical Medicine award from the Dean of the School of Medicine in 2010.

In 2013, Dr. Abraham joined Cleveland Clinic as director of Breast Oncology Program, where he leads several national and local clinical trials to find better treatment options for early stage, metastatic, triple negative and her-2 positive breast cancer patients. He is the vice chair of the Research Review Committee for the National Surgical Adjuvant Breast and Bowel Project NSABP and a member of the scientific advisory board. He is the national Principal Investigator of the NSABP FB -10 (Neratinib and TDM-1) clinical trial for her-2 positive metastatic breast cancer.

Dr. Abraham’s primary focus and passion is taking care of patients with breast cancer. He has been selected by Cleveland Magazine and Newsweek as the top oncologist locally and nationally, respectively.

Professional Highlights

  • Professor of Medicine, Cleveland Clinic Lerner College of Medicine
  • Co-Principal Investigator, Leading Academic Participating Sites (LAPS), National Cancer Institute  grant for the Case Comprehensive Cancer Center (2014-2017)
  • Member, Breast Cancer Committee, NRG Oncology (2015-18)
  • Member, Translational Research Committee, NRG Oncology (2015-18)
  • Principal Investigator of NSABP for Cleveland Clinic (2013 to present)
  • Vice Chair, Research Review Committee, NSABP Foundation (2013-2016)
  • Member of Breast Cancer Working Group, NSABP (2010-2013)
  • Founding Editor of Bethesda Handbook of Clinical Oncology, Wolter Kluwer, Philadelphia (5th edition)
  • Chief Editor, Emerging Cancer Therapeutics, Demos, New York
  • Editor, Community and Supportive Care Oncology (Frontline Communications, NJ)
  • Editor, Breast Cancer Management and Treatment (London, U.K)
  • Associate Editor, ASCO Post (Harborside Press, NY)
  • Board of Directors, American Cancer Society, South Atlantic Division (2007-2010)
      • Editorial Board Member:
        • Journal of Breast Cancer Management, Future Science Group, London, U.K, Oncology and Biotechnology News, New Jersey, Expert Review of Anticancer Therapy, Future Science Group, London, U.K.
      • Manuscript Reviewer:
        • Lancet Oncology, Lancet            
        • Journal of Clinical Oncology, ASCO
        • Clinical Cancer Research Focus, AACR
        • Human Bain Mapping
        • Expert Review of Immunotherapy
        • Clinical Breast Disease
        • British Journal of Cancer, Nature Publications Group
        • Annals of Saudi Medicine
        • Clinical Cancer Research, AACR
        • Expert Review of Anticancer Therapy
        • Cancer: American Cancer Society
        • Cancer Chemotherapy and Pharmacology

Education & Fellowships

Fellowship - National Cancer Institute
Medical Oncology
Bethesda, MD USA
2001
Fellowship - National Heart, Lung and Blood Institute
Hematology
Bethesda, MD USA
1999
Residency - University of Connecticut
Internal Medicine
Farmington, CT USA
1997
Medical School - Calicut Medical College
Calicut, Kerala, India
1991
Undergraduate - Calicut Medical College
Calicut, Kerala, India
1983

Certifications

  • Internal Medicine- Medical Oncology
  • Internal Medicine

Specialty Interests

Breast Cancer treatment, Clinical Trials

Awards & Honors

  • Teacher of the Year Award: Oncology, Taussig Cancer Institute, Cleveland Clinic, 2016
  • Top Doctors in Cleveland 2014, 2015 and 2016 Cleveland Magazine
  • Top Cancer Doctors in U.S, Newsweek, 2015
  • U.S. News Top Doctor, Castle Connolly Medical Ltd, 2010 to 2016    
  • Selected to the Gold Human Honor Society (GHHS), 2011
  • “Pink Tie Guy” – Selected by Susan G. Komen for the Cure, WV 2010
  • Dean’s Award for Excellence in Clinical Medicine, School of Medicine, West Virginia University, 2010
  • Quality Award (Customer Satisfaction), West Virginia University Hospitals, 2006-2013
  • President of India, Her Excellency, Smt. Pratibha Patil “Vaidya Bhooshan”, by the Pazhassi Raja Trust, New Delhi, India, 2010
  • Bonnie Wells Wilson Eminent Scholar and Distinguished Professor in Breast Cancer Research, 2009
  • Outstanding Achievement in Medicine, Kerala Center, India League, New York, 2008
  • Outstanding Faculty Award, Department of Medicine, West Virginia University, 2007
  • STAR Award for customer service, West Virginia University Hospital, 2006
  • Clinician of the Year Award, Department of Medicine, West Virginia University, 2006
  • Volunteer of the Year Award for the state of West Virginia, American Cancer Society (ACS) 2006

Additional Training

  • Senior Fellow, Developmental Therapeutics, National Cancer Institute 2001
  • Leadership Development for Physicians in Academic Health Centers, School of Public Health, Harvard, Boston. 2006

Innovations & Patents

    1. Population Based Molecular Prognosis of Breast Cancer by Transcriptional Profiling by 28 Gene Assay, 2007 (Provisional Serial Number: 60/919,369
    2. Nonlinear Characterization of Breast Cancer using Multi-Compression 3D Ultrasound Elastography (Patent pending) Nonlinear Characterization of Breast Cancer using Multi-Compression 3D Ultrasound Elastography (Patent pending)

Memberships

  • American Society of Clinical Oncology (ASCO)
  • American College of Physicians (ACP)
  • American Association of Cancer Research (AACR)

Treatment & Services

  • 2nd Opinion Evaluations
  • Blood Tests
  • Blood Transfusion
  • Cancer
  • Cancer Supportive Care
  • Chemoprevention
  • Chemotherapy
  • Clinical Drug Trials
  • Clinical Trials
  • Endocrine Aspects of Cancer
  • Endocrine Treatment
  • High Risk Breast Cancer
  • Immunotherapy
  • Targeted Treatment
  • Women's Health

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 11/8/2016, Dr. Abraham has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Abraham receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Pfizer, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English

Patient Satisfaction Reviews

Learn About Our Survey

Criteria

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Cleveland Clinic.